MediPharm Labs (MEDIF) AI Stock Analysis
Top Page
MediPharm Labs
(Other OTC:MEDIF)
No summary available
MediPharm Labs (MEDIF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $20.93M
- Dividend Yield
- ―
- Average Volume (3M)
- 53.46K
- Price to Earnings (P/E)
- -5.6
- Beta (1Y)
- -0.14
- Revenue Growth
- -5.84%
- EPS Growth
- 43.71%
- Country
- US
- Employees
- 127
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
MediPharm Labs Business Overview & Revenue Model
Company Description
MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across C...
MediPharm Labs Earnings Call Summary
The call emphasized strong operational and financial recovery: return to profitability, highest adjusted EBITDA since 2019, robust margin expansion, meaningful sequential revenue growth driven by international markets (notably Germany), successful Phase II LiBBY clinical results validating the pharmaceutical platform, and balance sheet strength. Headwinds include a material 30% VAC reimbursement cut that reduced Canadian medical revenue, ongoing pricing pressure and competition in key markets (Germany), and broader prescribing/reimbursement uncertainties. Overall, the positive operational execution, clinical validation, and improved profitability notably outweigh the identified challenges.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management's guidance emphasized disciplined, margin‑focused growth in 2026 and beyond—prioritizing regulated medical markets, selective M&A, geographic expansion (France, Brazil, New Zealand, U.K.), and non‑smokable/pharma formats (oils and a metered‑dose inhaler dossier submitted). They pointed to Q2 metrics that underpin this plan: revenue of $10.0M (+11% sequential), international medical $5.8M (~58% of revenue, +26% sequential) with Germany +45% sequential/+33% YoY, Canadian medical $2.3M (from $3.0M), Canadian adult use $1.5M (+34% sequential); gross profit $4.3M (43% margin, +30% vs Q1, +13% YoY); operating expenses $4.0M (‑44% YoY, ‑4% sequential); adjusted EBITDA +$0.9M (second consecutive positive quarter, best since 2019) and positive net income (first profitable quarter since 2019). They also reiterated balance‑sheet flexibility to fund growth with $9.9M cash, virtually no debt, ownership of 2 facilities appraised >$15M, Q1 restructuring to deliver >$1M annualized savings, plans to mitigate the VAC reimbursement cut (30% reduction from $8.50 to $6/gram) via cost, supply‑chain and mix actions, and expected H2 shipments/replenishments for Brazil and New Zealand.
MediPharm Labs Peers Comparison
Overall Rating
TSE:INNO56Neutral
TSE:ROMJ45Neutral
TSE:PCLO42Neutral
TSE:AVCN41Neutral
TSE:OILS40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:INNO | 56Neutral | CAD 8.55M | -6.55 | -19.37% | ― | -19.20% | 42.54% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:ROMJ | 45Neutral | CAD 25.34M | -15.24 | -4.00% | ― | 16.66% | -1007.41% |
| TSE:PCLO | 42Neutral | CAD 9.34M | -2.67 | 28.59% | ― | 0.90% | 57.73% |
| TSE:AVCN | 41Neutral | CAD 14.11M | -3.24 | -108.44% | ― | -0.23% | -142.54% |
| TSE:OILS | 40Underperform | CAD 3.40M | -1.75 | -43.92% | ― | -18.30% | -397.37% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MEDIF | Medipharm Labs (Otc) | 0.05 | -0.00 | -7.69% | |
| TSE:PCLO | Pharmacielo | 0.05 | 0.01 | 11.11% | |
| TSE:OILS | Nextleaf Solutions | 0.02 | -0.04 | -66.67% | |
| TSE:ROMJ | Rubicon Organics | 0.38 | -0.13 | -25.00% | |
| TSE:AVCN | Avicanna Inc | 0.10 | -0.16 | -60.38% | |
| TSE:INNO | Innocan Pharma Corporation | 1.90 | -16.10 | -89.44% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.